Research programme: vascular endothelial growth factor receptor antagonists - PhiloGene

Drug Profile

Research programme: vascular endothelial growth factor receptor antagonists - PhiloGene

Alternative Names: PLG101; PLG201; PLG202

Latest Information Update: 22 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhiloGene
  • Developer Alcon; PhiloGene
  • Class Cytokines; Proteins
  • Mechanism of Action Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic retinopathy; Solid tumours

Most Recent Events

  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 07 Aug 2009 Preclinical development is ongoing in Israel and the US
  • 25 Jul 2008 Preclinical trials in Age-related macular degeneration in Israel (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top